The mRNA ac4C writer NAT10 stimulates DNA damage repair to promote cisplatin chemoresistance in bladder cancer, identifying NAT10 inhibition as a potential therapeutic approach to enhance cisplatin sensitivity.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2023) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: